INTRODUCTION {#s1}
============

Malignant mesothelioma (MM) is a highly aggressive carcinoma usually involving the pleura or peritoneum. Between 1994 and 2008, a total of 92,253 mesothelioma deaths has been reported to the World Health Organization from 83 countries, and the crude and age-adjusted mortality rates of mesothelioma were estimated as 6.2 and 4.9 per million population, respectively \[[@R1]\]. Moreover, an incidence peak was expected around 2020 according to the widespread exposure to asbestos \[[@R2]\]. Unfortunately, the patients suffering from MM showed poor response to the drug, and their median survival period was only 8 months (range 1∼69 months) \[[@R3]\].

The diagnosis of carcinoma is usually based on histopathological examination on tissue or cytological specimens. Because morphological features of MM mimic those of a variety of other carcinomas, immunohistochemical markers have been used to improve the diagnostic performance, as recommended by International Mesothelioma Interest Group \[[@R4]\]. Whereas, several follow-up studies reported that the misdiagnosis rate of MM was high (10% ∼44%) \[[@R5]--[@R7]\], even much higher (65%) in its pleural localization \[[@R8]\]. So, it is necessary to evaluate the diagnostic accuracy of the markers.

D2-40 is a commercial monoclonal antibody directed against the M2a antigen, which is associated with testicular and extratesticular seminomas and intratubular germ cell neoplasms \[[@R9]\]. Also, D2-40 is a marker for lymphatic endothelium and derived carcinomas \[[@R10]\]. In the past decade, D2-40 has been widely used as an immunostaining marker of diagnosing MM \[[@R4], [@R11]--[@R14]\]. However, the studies about its diagnostic accuracy obtained inconsistent results. Therefore, our study aimed to assess the overall accuracy of D2-40 immunostaining for diagnosing MM through a meta-analysis.

MATERIALS AND METHODS {#s2}
=====================

Literature search and study selection {#s2_1}
-------------------------------------

We conducted an independent literature search to identify the relevant studies in PubMed, EMBASE, Web of Science, Scopus and the Cochrane database up to December 31, 2016. The search terms were "Mesothelioma", and "D2-40", and "sensitivity or specificity or accuracy". The reference lists of eligible studies were also manually searched to find the potential studies.

The included studies should meet all the following criteria: (1) it was an original study using D2-40 immunostaining to diagnose MM; (2) there was a diagnostic standard for MM; (3) there were sufficient data to generate a 2 × 2 table for calculating sensitivity and specificity; (4) it was published in English; (5) it involved at least 10 participants for case or control group.

Two independent researchers (CH and BW) screened and selected the eligible articles. Any disagreement between the two researchers was resolved by consultation with a third researcher (YCS).

Data extraction and quality assessment {#s2_2}
--------------------------------------

Two researchers (CH and BW) manually extracted the following data from each study: author; publication year; research country; participant; specimen; specimen preparation method; D2-40 antibody (clone, dilution, source); cutoff of positive immunostaining; the number of true-positive, false-positive, true-negative, and false-negative results; study design; and blinding. At the same time, the methodological quality of these studies was evaluated using the Quality Assessment for Diagnostic Accuracy Studies (QUADAS) score \[[@R15]\]. The discrepancies were resolved through consultation with a third researcher (YCS).

Statistical analyses {#s2_3}
--------------------

The following parameters of diagnostic accuracy, together with their 95% confidence interval (95% CI), were calculated: sensitivity, specificity, positive/negative likelihood ratio (PLR/NLR), and diagnostic odds ratio (DOR). Forest plots for sensitivity and specificity were constructed. Summary receiver operating characteristic (SROC) curve was generated, and area under the cure (AUC) was calculated to assess the overall diagnostic performance. Publication bias was tested using Deeks' funnel plots \[[@R16]\].

Potential heterogeneity among included studies was evaluated using the I^2^ inconsistency test. I^2^ \> 50% suggested substantial heterogeneity, which was subsequently analyzed through a meta-regression analysis to determine possible sources of heterogeneity among the studies.

All the statistical analysis was completed by Meta-DiSc XI (Cochrane Colloquium, Barcelona, Spain) and STATA 12.0 (Stata Corporation, TX, USA) software. All statistical tests were two-sided, and statistical significance was set at *P* \< 0.05.

RESULTS {#s3}
=======

Characteristics of included studies {#s3_1}
-----------------------------------

A total of 22 studies were identified according to the inclusion criteria in our meta-analysis \[[@R5], [@R8], [@R17]--[@R36]\]. The process of selecting studies was shown in Figure [1](#F1){ref-type="fig"}. The characteristics of these studies were listed in Table [1](#T1){ref-type="table"}. Overall, these studies originated from 8 countries, and involved 2,264 participants comprising 862 MM cases and 1,402 controls. The sample size of these studies varied from 20 to 282, with an average size of 103 participants. Lung carcinoma (778/1402, 55.5%) was the predominating control group ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}). Four studies performed D2-40 immunostaining of cell blocks from the effusions \[[@R17]--[@R20]\] and the remaining 18 studies assayed the tissues from surgical section, biopsy and/or autopsy \[[@R5], [@R8], [@R21]--[@R36]\]. As shown in Table [2](#T2){ref-type="table"}, 20 studies had QUADAS scores ≥ 9, suggesting the reliability of our meta-analysis results.

![Flow diagram of literature search](oncotarget-08-64407-g001){#F1}

###### Characteristics of included studies

  Author (Ref)              Year   Country     Participants   Specimen   Specimen preparation                  Clone   Dilution      Source     Cut-off
  ------------------------- ------ ----------- -------------- ---------- ------------------------------------- ------- ------------- ---------- -----------------------------------------------------------------------------------------
  Bassarova AV \[[@R17]\]   2006   Norway      282            PE,PTE     Cell block                            D2-40   1:200         Dako       Membranous staining
  Saad RS \[[@R18]\]        2006   USA         40             PE         Cell block                            D2-40   1:50          Signet     Membranous staining
  Bhalla R \[[@R19]\]       2007   USA         20             PE,PTE     Cell block                            D2-40   1:100         Dako       Membranous staining
  Hyun TS \[[@R20]\]        2012   USA         32             PE         Cell block                            D2-40   1:50          Dako       Membranous staining
  Ordóñez NG \[[@R21]\]     2005   USA         163            Tissue     Tissue section                        D2-40   1:50          Signet     Membranous staining
  Chu AY \[[@R22]\]         2005   USA         178            Tissue     Tissue block                          D2-40   1:25          Signet     Membranous and/or Cytoplasmic staining
  Müller AM \[[@R23]\]      2006   Germany     112            Tissue     Tissue section                        D2-40   1:50          DCS        Membranous and/or Cytoplasmic staining
  Ordóñez NG \[[@R24]\]     2006   USA         85             Tissue     Tissue section                        D2-40   1:25          Signet     Membranous staining
  Comin CE \[[@R25]\]       2007   Italy       55             Tissue     Surgical resection                    D2-40   Pre-diluted   Signet     Membranous staining
  Mimura T \[[@R26]\]       2007   Japan       132            Tissue     Major resection                       D2-40   1:50          Dako       Membranous staining
  Padgett DM \[[@R27]\]     2008   USA         145            Tissue     Surgical resection, autopsy, slides   D2-40   1:100         Signet     Membranous or Cytoplasmic staining (\> 10% cells stained, moderate or strong intensity)
  Amatya VJ \[[@R28]\]      2009   Japan       160            Tissue     Surgical resection, autopsy           D2-40   Pre-diluted   Nichirei   Membranous and/or Cytoplasmic staining
  Deniz H \[[@R29]\]        2009   Turkey      73             Tissue     Tissue section                        D2-40   NA            Dako       Membranous staining (\> 5% cells stained)
  Takeshima Y \[[@R30]\]    2009   Japan       72             Tissue     Surgical section                      D2-40   Pre-diluted   Nichirei   Membranous and/or Cytoplasmic staining
  Hu YC \[[@R31]\]          2010   USA         67             Tissue     Surgical resection, biopsy            D2-40   1:100         Dako       Membranous and/or Cytoplasmic staining (\> 10% cells stained)
  Kao SC \[[@R32]\]         2011   Australia   101            Tissue     Surgical section                      D2-40   1:100         Signet     Membranous staining
  Comin CE \[[@R33]\]       2014   Italy       247            Tissue     Surgical section, biopsy              D2-40   RTU           Ventana    Membranous staining
  Guo Z\[[@R8]\]            2016   China       78             Tissue     Biopsy                                D2-40   RTU           Dako       NA
  Kawai T \[[@R34]\]        2016   Japan       33             Tissue     Biopsy, autopsy, excision             D2-40   RTU           Nichirei   \> 10% cells stained
  Carbone M \[[@R5]\]       2016   USA         55             Tissue     Biopsy                                D2-40   NA            Dako       NA
  Amatya VJ \[[@R35]\]      2017   Japan       60             Tissue     Surgical section                      D2-40   Pre-diluted   Nichirei   Membranous staining
  Kushitani K \[[@R36]\]    2017   Japan       74             Tissue     Biopsy, autopsy, surgical section     D2-40   Pre-diluted   Nichirei   Membranous staining

PE: Pleural effusion; PTE: Peritoneal effusion; NA: Not available; RTU: Ready to use.

###### Diagnostic performance, design, and quality of included studies

  Author (Ref)              Cases   Controls   TP   FP    FN   TN    Design   Blinded?   QUADAS
  ------------------------- ------- ---------- ---- ----- ---- ----- -------- ---------- --------
  Bassarova AV \[[@R17]\]   32      250        32   128   0    122   NA       NA         8
  Saad RS \[[@R18]\]        20      20         17   0     3    20    R        Yes        8
  Bhalla R \[[@R19]\]       10      10         10   0     0    10    R        NA         9
  Hyun TS \[[@R20]\]        11      21         9    0     2    21    R        Yes        10
  Ordóñez NG \[[@R21]\]     40      123        29   8     11   115   NA       NA         11
  Chu AY \[[@R22]\]         53      125        51   27    2    98    R        NA         12
  Müller AM \[[@R23]\]      36      76         22   27    14   49    NA       NA         10
  Ordóñez NG \[[@R24]\]     40      45         37   6     3    39    NA       NA         11
  Comin CE \[[@R25]\]       15      40         14   8     1    32    R        NA         9
  Mimura T \[[@R26]\]       66      66         56   3     10   63    R        NA         11
  Padgett DM \[[@R27]\]     44      101        38   4     6    97    R        NA         12
  Amatya VJ \[[@R28]\]      80      80         74   13    6    67    R        NA         12
  Deniz H \[[@R29]\]        37      36         19   0     18   36    R        NA         11
  Takeshima Y \[[@R30]\]    45      27         39   7     6    20    R        NA         10
  Hu YC \[[@R31]\]          36      31         25   2     11   29    R        NA         10
  Kao SC \[[@R32]\]         80      21         80   0     0    21    R        NA         9
  Comin CE \[[@R33]\]       75      172        73   25    2    147   R        NA         10
  Guo Z \[[@R8]\]           43      35         38   24    5    11    R        NA         12
  Kawai T \[[@R34]\]        22      11         17   3     5    8     P        NA         11
  Carbone M \[[@R5]\]       10      45         8    10    2    35    R        NA         10
  Amatya VJ \[[@R35]\]      31      29         22   9     9    20    R        Yes        12
  Kushitani K \[[@R36]\]    36      38         35   23    1    15    R        NA         11

NA: Not available; P: Prospective; R: Retrospective; FN: False negative; FP: False positive; TN: True negative;

TP: True positive; QUADAS: Quality assessment for diagnostic accuracy studies.

Diagnostic accuracy of D2-40 immunostaining {#s3_2}
-------------------------------------------

The pooled sensitivity and specificity of D2-40 for diagnosing MM was 0.86 (95% CI: 0.84--0.89) and 0.77 (95% CI: 0.74--0.79), respectively (Figure [2](#F2){ref-type="fig"}). The AUC of SROC curve was 0.93 (Figure [3A](#F3){ref-type="fig"}). Other parameters of D2-40 for MM were listed in Table [3](#T3){ref-type="table"}.

![Forest plots of sensitivity and specificity for diagnosing malignant mesothelioma using D2-40 immunostaining](oncotarget-08-64407-g002){#F2}

![Summary receiver operating characteristic (SROC) curves for diagnosing malignant mesothelioma (MM) and its subtypes using D2-40 immunostaining\
(**A**) MM (**B**) Epithelioid MM (**C**) Biphasic MM (**D**) Sarcomatoid MM. The SROC curves with confidence and prediction regions around mean operating sensitivity and specificity point analyses of D2-40. AUC, Area under the curve.](oncotarget-08-64407-g003){#F3}

###### Accuracy of D2-40 immunostaining for diagnosing malignant mesothelioma (MM)

  Carcinoma        No. of studies   Cases   Controls   AUC    SEN \[95% CI\]        SPE \[95% CI\]        PLR \[95% CI\]         NLR \[95% CI\]        DOR \[95% CI\]
  ---------------- ---------------- ------- ---------- ------ --------------------- --------------------- ---------------------- --------------------- -------------------------
  MM               22               862     1402       0.93   0.86 \[0.84, 0.89\]   0.77 \[0.74, 0.79\]   5.15 \[3.30, 8.03\]    0.18 \[0.12, 0.27\]   40.37 \[19.97, 81.61\]
  Epithelioid MM   16               540     1020       0.96   0.92 \[0.89, 0.94\]   0.84 \[0.82, 0.87\]   6.56 \[4.06, 10.58\]   0.10 \[0.06, 0.18\]   85.38 \[51.85, 140.60\]
  Biphasic MM      9                85      559        0.94   0.80 \[0.70, 0.88\]   0.90 \[0.87, 0.92\]   8.27 \[4.22, 16.21\]   0.24 \[0.08, 0.70\]   43.14 \[15.53, 119.82\]
  Sarcomatoid MM   10               131     659        0.83   0.65 \[0.56, 0.73\]   0.84 \[0.81, 0.87\]   3.29 \[1.75, 6.16\]    0.52 \[0.29, 0.92\]   6.93 \[2.05, 23.47\]
  Pleural MM       13               536     707        0.93   0.85 \[0.82, 0.88\]   0.81 \[0.78, 0.84\]   5.12 \[2.94, 8.90\]    0.19 \[0.11, 0.33\]   42.98 \[15.21, 121.39\]

AUC, Area under the curve; CI: Confidential interval; SEN, Sensitivity; SPE, Specificity; PLR: Positive likelihood ratio; NLR: Negative likelihood ratio; DOR: Diagnostic odds ratio.

After subgroup analysis, diagnostic indices of D2-40 for each subtype of MM (epithelioid, or biphasic, and sarcomatoid) were shown in Figure [3B--3D](#F3){ref-type="fig"} and Table [3](#T3){ref-type="table"}. Parameters of D2-40 for pleural MM were also listed in Table [3](#T3){ref-type="table"}.

Meta-regression {#s3_3}
---------------

I^2^ values for diagnostic performance indices were as follows: sensitivity, 82.8% (*P* = 0.00); specificity, 93.1% (*P* = 0.00); PLR, 94.2% (*P* = 0.00); NLR, 81.6% (*P* = 0.00); and DOR, 77.3% (*P* = 0.00). These suggested high heterogeneity among included studies. Therefore, a meta-regression analysis was performed based on eight variates: country of origin (USA vs others); sample size (\< 100 or ≥ 100); specimen type (effusion vs tissue); D2-40 antibody dilution (\< 1:50 vs others); cut-off value (Membranous staining vs others); study design (prospective vs others); and blinding (blind vs Not available); QUADAS score (\< 9 vs ≥ 9). None of these covariates was found to be a source of heterogeneity (all *P* ≥ 0.05, Table [4](#T4){ref-type="table"}).

###### Meta-regression of potential heterogeneity among the included studies

  Covariates             No. of studies   Coefficient   SE     RDOR (95% CI)         *P* value
  ---------------------- ---------------- ------------- ------ --------------------- -----------
  Country                                                                            
   USA                   9                --0.66        0.77   0.52 (0.10--2.76)     0.41
   others                13                                                          
  Sample size                                                                        
   \< 100                13               0.87          0.70   2.39 (0.52--10.96)    0.24
   ≥ 100                 9                                                           
  Specimen                                                                           
   Effusion              4                --1.32        1.78   0.27 (0.01--13.01)    0.47
   Tissue                18                                                          
  D2-40 dilution                                                                     
   \< 1:50               5                --1.10        0.96   0.33 (0.04--2.72)     0.27
   others                17                                                          
  Cut-off                                                                            
   Membranous staining   13               --1.52        0.72   0.22 (0.05--1.04)     0.05
   others                9                                                           
  Study Design                                                                       
   Prospective           1                --0.14        1.60   1.15 (0.04--37.21)    0.93
   others                21                                                          
  Blinding                                                                           
   Yes                   3                −0.97         1.30   0.38(0.02--6.53)      0.47
   NA                    19                                                          
  QUADAS score                                                                       
   \< 9                  2                1.08          2.10   2.95 (0.03--289.83)   0.62
   ≥ 9                   20                                                          

SE: Standard error; RDOR: Relative diagnostic odds ratio; CI: Confidential interval; NA: Not available; QUADAS: Quality assessment for diagnostic accuracy studies.

Publication bias {#s3_4}
----------------

The slope coefficient of Deeks' funnel plot was associated with a *P* value of 0.48, suggesting symmetry in the data and low likelihood of such kind of bias among the included studies (Figure [4](#F4){ref-type="fig"}).

![Deeks' funnel plot to assess the likelihood of publication bias\
The *P* value of 0.48 for the slope coefficient suggests symmetry in the data and a low likelihood of publication bias.](oncotarget-08-64407-g004){#F4}

DISCUSSION {#s4}
==========

The search for biomarkers, a cost-effective means of MM management, has been on-going for the past years \[[@R37]\]. D2-40 has emerged as a promising candidate, but the results of the studies remain controversial \[[@R20], [@R33], [@R36]\]. In our study, we determined the overall accuracy of D2-40 immunostaining in diagnosing MM through a meta-analysis.

Our meta-analysis found the pooled sensitivity and specificity was 0.86 and 0.77 respectively, suggesting a rate of missed diagnoses (14%) and misdiagnosis (23%) of D2-40 for diagnosing MM. The pooled DOR of D2-40 for MM was 40.37, which indicates a modest level of overall accuracy. The pooled PLR value of 5.15 suggests that the patients with MM have an approximately 5-fold higher chance of giving a positive D2-40 result than do patients without MM. At the same time, the pooled NLR was 0.18, indicating that a negative D2-40 result is 18% likely to be a false negative, which is not low enough to rule out MM. Thus, these findings suggested that D2-40 should be combined with other markers to improve the diagnostic accuracy. For example, several studies reported that D2-40 showed low specificity in distinguishing MM from ovarian carcinomas \[[@R17], [@R20], [@R22]\]. If the differential diagnosis of peritoneal MM from ovarian carcinomas is required, clinical history of the patient should be an important factor for evaluation. At the same time, the ovarian carcinoma markers, estrogen receptor etc., should be added into the immunohistochemical panel for avoiding a false-positive diagnosis of MM \[[@R38]\].

MM has distinctive histological subtypes: epithelioid (60%∼80%), sarcomatoid (\< 10%), and biphasic (10%∼15%, composed of both epithelioid and sarcomatoid components) \[[@R39]\]. Our study further determined the diagnostic performance of D2-40 for these subtypes and found the performance of D2-40 for diagnosing epithelioid MM and biphasic MM is better than that for sarcomatoid MM. It indicated the reactivity to D2-40 antibody differed among these subtypes of MM. A relatively low pooled sensitivity (0.65, 95% CI: 0.56--0.73) for sarcomatoid MM was obtained in our meta-analysis. However, Chirieac LR \[[@R40]\] have reported that all the 24 (100%) cases of sarcomatoid MM were positive for D2-40 staining in their study, which was not included in our meta-analysis for lack of control group. Further work should be performed to elucidate this issue.

In diagnostic practice, pleural MM can easily be confused with metastatic carcinomas with the pleura involvement. Our meta-analysis has performed a subgroup analysis of pleural MM. We found that the sensitivity, specificity, and AUC of D2-40 for diagnosing pleural MM were 0.85, 0.81 and 0.93, respectively. However, interpretation should be with caution when differentiating pleural MM from lung small cell carcinomas (SCC), because it was reported that D2-40 can stained 77% of lung SCC \[[@R5]\]. Recently, novel markers, such as BAP1 \[[@R5]\], MUC4 \[[@R35]\], fibulin-3 \[[@R41]\], have been used to improve the diagnostic accuracy of D2-40 for pleural MM.

Compared with histological diagnosis, cytological diagnosis of MM is minimally invasive and more easily performed. Because only 4 studies using cytology of effusions to diagnose MM can be included in our meta-analysis, the accuracy of diagnosing MM using cytology is hard to be evaluated accurately now. But the difference of biological behavior among the subtypes of MM should be considered when using cytological diagnosis. Epithelioid MM cells readily shed into the pleural or peritoneal space, which can be identified from pleural or peritoneal effusions \[[@R42]\]. While, sarcomatoid MM cells generally do not shed into the pleural or peritoneal space, which leads to poor performance of cytological diagnosis \[[@R42]\]. Thus, cytology-only approach should be not suitable for diagnosing sarcomatoid MM and biphasic MM.

Because both benign and malignant mesothelial cells can react to D2-40 antibody \[[@R22], [@R43]\], it is needed to distinguish MM from reactive mesothelial hyperplasia in diagnostic practice. Several aspects (such as cellularity, papillae, zonation, growth pattern, vascularity and stromal invasion) should be considered \[[@R4], [@R39], [@R44]\]. A new tool, combining molecular data and computational analysis, has been applied for this kind of differential diagnosis \[[@R45]\].

In addition, the operation procedure of D2-40 immunostaining was not uniformed in the included studies. First, though all the included studies used D2-40 clone, its dilution factors ranged from 1:25 to 1:200. Second, cut-off value of positive staining is not consistent among the included studies. According to our experience in D2-40 immunostaining (D2-40 clone, 1:100, Dako, membrane staining), optimal condition, standard operation procedure, and reliable quality control are very important for obtaining satisfactory immunostaining results.

The findings of this meta-analysis should be interpreted with caution because of several limitations. We applied strict inclusion criteria, which may be good for reducing selection bias, but led to only a small set of studies could be included. In addition, we observed the substantial heterogeneity across the included studies, but we were unable to identify its source using meta-regression analysis. Future work should aim to decrease the risk of bias.

CONCLUSIONS {#s5}
===========

In summary, our findings indicated that the accuracy of D2-40 immunostaining may be not enough to diagnose MM alone. The results of D2-40 immunostaining should be interpreted in combination with those of other markers. Novel promising markers are also needed to be explored to improve the diagnostic accuracy.

SUPPLEMENTARY MATERIALS TABLE {#s6}
=============================
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